Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $139.76 (market cap $24.42B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is far larger — about 3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and TG Therapeutics Inc for 16 Days on average.
| SOXL | TGTX | |
|---|---|---|
Market Cap | $24.42B | $8.16B |
Volume | 100,232,380 | 1,735,121 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $59.06 |
52-Week Low | $30.81 | $26.94 |
Typical Hold Time | 15 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $139.76, down 12.05% with a bearish technical signal. The fund faces volatility from its 3x leverage on semiconductor stocks, which have shown mixed performance amid strong AI demand but regulatory and market risks. Recent news highlights sector rebounds and institutional selling, while technical indicators show neutral oscillators and key support at $134.
Outlook is cautious due to leverage amplifying sector swings; opportunities exist if semiconductor fundamentals hold, but risks include tariff concerns and overcrowded trades. Investors should weigh high volatility against AI-driven growth potential.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
